全部文献期刊会议图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Sajjad Molavipordanjani , Shabanali Khodashenas , Seyed Mohammad Abedi ...
来源:[J].European Journal of Pharmaceutical Sciences(IF 2.987), 2020
摘要:... Therefore, in this study, a radiolabel HER2 targeted exosomes ( 99m Tc-exosomes) was provided for tumor imaging. These exomes are obtained from genetically engineered cells and possessed DARPin G3 as a ligand for HER2 receptors. These exosomes were radiolabeled using fac -[ 9...
作者:Carlos Casterá , Laia Bernet
来源:[J].Annals of Diagnostic Pathology(IF 0.975), 2020, Vol.45
摘要:Abstract(#br)Assessment of HER2 biomarker in invasive breast carcinoma patients allows a specific therapeutic approach. Clinical guidelines indicate immunohistochemistry (IHC) and in situ hybridization (ISH) to test HER2, however both have drawbacks which results in low repr...
作者:Jingjing Bao , Wenjun Zhang , Weixian Zhou ...
来源:[J].Talanta(IF 3.498), 2020, Vol.215
摘要:Abstract(#br)Human epidermal growth factor receptor 2 (HER2)-positive is a particularly aggressive type of the breast cancer. Because of the evidence has revealed that accurate HER2 status detection is crucial for prognosis and treatment strategy selection, great effort has b...
作者:Iosune Baraibar , Laura Mezquita , Ignacio Gil-Bazo ...
来源:[J].Critical Reviews in Oncology / Hematology(IF 4.637), 2020, Vol.148
摘要:... In addition, 2 %–4 % of patients with NSCLC harbor human epidermal growth factor receptor 2 gene (HER2) mutations, being the 90 % of them exon 20 insertions. These mutations confer intrinsic resistance to available EGFR tyrosine kinase inhibitors (TKIs) and anti-HER2 trea...
作者:Florian Guisier , Catherine Dubos-Arvis , Florent Viñas ...
来源:[J].Journal of Thoracic Oncology(IF 4.473), 2020, Vol.15 (4), pp.628-636
摘要:... This study was undertaken to determine ICI efficacy against BRAF-, HER2-, MET-, and RET -NSCLC in a real-world setting.(#br)Methods(#br)In this retrospective, multicenter study in ICI-treated BRAF-, HER2-, MET- or RET -NSCLCs, we analyzed clinical characteristics and outco...
作者:Mantosh Kumar Singh , Sai Kiran S.S. Pindiprolu , Bharat Kumar Reddy Sanapalli ...
来源:[J].International Journal of Biological Macromolecules(IF 2.596), 2020, Vol.150, pp.631-636
摘要:... Liposomal formulation of CAP was prepared by film hydration method using cholesterol-THP conjugate (CTHP-CAP-LPs) to achieve active targeting through HER2 receptors. CTHP-CAP-LPs significantly improved the specificity and efficacy of CAP by improving cell uptake, cytotoxicity...
作者:Astrid De Cuyper , Marc Van Den Eynde , Jean-Pascal Machiels
来源:[J].Clinical Colorectal Cancer(IF 1.8), 2020
摘要:... Several retrospective trials suggest that human epidermal growth factor receptor 2 ( HER2 ) amplification could be a predictive biomarker of resistance to anti-EGFR mAbs in patients with metastatic RAS and RAF wild-type mCRC. Dual HER2 inhibition with trastuzumab plus lapatin...
作者:M. Jebbink , A.J. de Langen , M.C. Boelens ...
来源:[J].Cancer Treatment Reviews(IF 6.024), 2020, Vol.86
摘要:... One of these alterations involves HER2, a member of the ERBB family of tyrosine kinase receptors. Despite that HER2 alterations in NSCLC have been studied for years, there is still no consensus about subgroup definitions. In this review HER2 alterations in NSCLC are disc...
作者:Yuanping Hu , Shouman Wang , Nianhua Ding ...
来源:[J].Clinical Breast Cancer(IF 2.422), 2020
摘要:... The relationship of the NLR and PLR with chemotherapy sensitivity and prognosis in luminal B-like (human epidermal growth factor receptor 2-negative [HER2 − ]) BC are not well studied.(#br)Patients and Methods(#br)The clinical data from 980 patients with luminal B-like (HER2...
作者:Aziza E. Abdelrahman , Hayam E. Rashed , Ehab Elkady ...
来源:[J].Annals of Diagnostic Pathology(IF 0.975), 2019, Vol.39, pp.42-52
摘要:... To define the useful prognostic markers for progression, we analyzed the immunohistochemical expression of fatty acid synthase (FASN), Her2/neu, and E2F1 in 60 cases of NMIBC who underwent TURBT and adjuvant intravesical bacillus-Calmette-Guérin (BCG). Their predicting role...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×